Cargando…
Identification of clinical and molecular features of recurrent serous borderline ovarian tumour
BACKGROUND: Serous borderline ovarian tumour (SBOT) is the most common type of BOT. Fertility sparing surgery (FSS) is an option for patients with SBOT, though it may increase the risk of recurrence. The clinical and molecular features of its recurrence are important and need to be investigated in d...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011028/ https://www.ncbi.nlm.nih.gov/pubmed/35434581 http://dx.doi.org/10.1016/j.eclinm.2022.101377 |
_version_ | 1784687603358892032 |
---|---|
author | Lu, Ziyang Lin, Fanghe Li, Tao Wang, Jinhui Liu, Cenxi Lu, Guangxing Li, Bin Pan, MingPei Fan, Shaohua Yue, Junqiu Huang, He Song, Jia Gu, Chao Li, Jin |
author_facet | Lu, Ziyang Lin, Fanghe Li, Tao Wang, Jinhui Liu, Cenxi Lu, Guangxing Li, Bin Pan, MingPei Fan, Shaohua Yue, Junqiu Huang, He Song, Jia Gu, Chao Li, Jin |
author_sort | Lu, Ziyang |
collection | PubMed |
description | BACKGROUND: Serous borderline ovarian tumour (SBOT) is the most common type of BOT. Fertility sparing surgery (FSS) is an option for patients with SBOT, though it may increase the risk of recurrence. The clinical and molecular features of its recurrence are important and need to be investigated in detail. METHODS: An internal cohort of 319 patients with SBOT was collected from Aug 1, 2009 to July 31, 2019 from the Obstetrics and Gynecology Hospital of Fudan University in China. An external cohort of 100 patients with SBOT was collected from Aug 1, 2009 to Nov 30, 2019 from the Shandong Provincial Hospital in China. The risk factors for the recurrence were identified by multivariate cox analysis. Several computational methods were tested to establish a prediction tool for recurrence. Whole genome sequencing, RNA-seq, metabolomics and lipidomics were used to understand the molecular characteristics of the recurrence of SBOT. FINDINGS: Five factors were significantly correlated with SBOT recurrence in a Han population: micropapillary pattern, advanced stage, FSS, microinvasion, and lymph node invasion. A random forest-based online recurrence prediction tool was established and validated using an internal cohort and an independent external cohort for patients with SBOT. The multi-omics analysis on the original SBOT samples revealed that recurrence is related to metabolic regulation of immunological suppression. INTERPRETATION: Our study identified several important clinical and molecular features of recurrent SBOT. The prediction tool we established could help physicians to estimate the prognosis of patients with SBOT. These findings will contribute to the development of personalised and targeted therapies to improve prognosis. FUNDING: JL was funded by MOST 2020YFA0803600, 2018YFA0801300, NSFC 32071138, and SKLGE-2118 to Jin Li; JY was funded by the Initial Project for Young and Middle-aged Medical Talents of Wuhan City, Hubei Province ([2014] 41); HH was funded by MOST 2019YFA0801900 and 2020YF1402600 to He Huang; JS was funded by NSFC 22,104,080; CG was funded by Natural Science Foundation of Shanghai 20ZR1408800 and NSFC82171633; BL was funded by Natural Science Foundation of Shanghai 19ZR1406800. |
format | Online Article Text |
id | pubmed-9011028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90110282022-04-16 Identification of clinical and molecular features of recurrent serous borderline ovarian tumour Lu, Ziyang Lin, Fanghe Li, Tao Wang, Jinhui Liu, Cenxi Lu, Guangxing Li, Bin Pan, MingPei Fan, Shaohua Yue, Junqiu Huang, He Song, Jia Gu, Chao Li, Jin EClinicalMedicine Articles BACKGROUND: Serous borderline ovarian tumour (SBOT) is the most common type of BOT. Fertility sparing surgery (FSS) is an option for patients with SBOT, though it may increase the risk of recurrence. The clinical and molecular features of its recurrence are important and need to be investigated in detail. METHODS: An internal cohort of 319 patients with SBOT was collected from Aug 1, 2009 to July 31, 2019 from the Obstetrics and Gynecology Hospital of Fudan University in China. An external cohort of 100 patients with SBOT was collected from Aug 1, 2009 to Nov 30, 2019 from the Shandong Provincial Hospital in China. The risk factors for the recurrence were identified by multivariate cox analysis. Several computational methods were tested to establish a prediction tool for recurrence. Whole genome sequencing, RNA-seq, metabolomics and lipidomics were used to understand the molecular characteristics of the recurrence of SBOT. FINDINGS: Five factors were significantly correlated with SBOT recurrence in a Han population: micropapillary pattern, advanced stage, FSS, microinvasion, and lymph node invasion. A random forest-based online recurrence prediction tool was established and validated using an internal cohort and an independent external cohort for patients with SBOT. The multi-omics analysis on the original SBOT samples revealed that recurrence is related to metabolic regulation of immunological suppression. INTERPRETATION: Our study identified several important clinical and molecular features of recurrent SBOT. The prediction tool we established could help physicians to estimate the prognosis of patients with SBOT. These findings will contribute to the development of personalised and targeted therapies to improve prognosis. FUNDING: JL was funded by MOST 2020YFA0803600, 2018YFA0801300, NSFC 32071138, and SKLGE-2118 to Jin Li; JY was funded by the Initial Project for Young and Middle-aged Medical Talents of Wuhan City, Hubei Province ([2014] 41); HH was funded by MOST 2019YFA0801900 and 2020YF1402600 to He Huang; JS was funded by NSFC 22,104,080; CG was funded by Natural Science Foundation of Shanghai 20ZR1408800 and NSFC82171633; BL was funded by Natural Science Foundation of Shanghai 19ZR1406800. Elsevier 2022-04-08 /pmc/articles/PMC9011028/ /pubmed/35434581 http://dx.doi.org/10.1016/j.eclinm.2022.101377 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Lu, Ziyang Lin, Fanghe Li, Tao Wang, Jinhui Liu, Cenxi Lu, Guangxing Li, Bin Pan, MingPei Fan, Shaohua Yue, Junqiu Huang, He Song, Jia Gu, Chao Li, Jin Identification of clinical and molecular features of recurrent serous borderline ovarian tumour |
title | Identification of clinical and molecular features of recurrent serous borderline ovarian tumour |
title_full | Identification of clinical and molecular features of recurrent serous borderline ovarian tumour |
title_fullStr | Identification of clinical and molecular features of recurrent serous borderline ovarian tumour |
title_full_unstemmed | Identification of clinical and molecular features of recurrent serous borderline ovarian tumour |
title_short | Identification of clinical and molecular features of recurrent serous borderline ovarian tumour |
title_sort | identification of clinical and molecular features of recurrent serous borderline ovarian tumour |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011028/ https://www.ncbi.nlm.nih.gov/pubmed/35434581 http://dx.doi.org/10.1016/j.eclinm.2022.101377 |
work_keys_str_mv | AT luziyang identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT linfanghe identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT litao identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT wangjinhui identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT liucenxi identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT luguangxing identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT libin identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT panmingpei identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT fanshaohua identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT yuejunqiu identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT huanghe identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT songjia identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT guchao identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour AT lijin identificationofclinicalandmolecularfeaturesofrecurrentserousborderlineovariantumour |